Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors
Conditions
Interventions
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Locations
48
United States
Columbia University Medical Center
New York, New York, United States
Memorial Sloan Kettering
New York, New York, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Sarah Cannon Cancer Center and Research Institute
Nashville, Tennessee, United States
MD Anderson Cancer Center
Houston, Texas, United States
LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie
Graz, Austria
Start Date
July 16, 2015
Primary Completion Date
April 4, 2018
Completion Date
July 28, 2020
Last Updated
June 4, 2021
NCT06898450
NCT01247597
NCT06658951
NCT06625775
NCT05101070
NCT05719558
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions